Potent antagonist of type 1 receptor lysophosphatidic acid (LPA1), selective over other LPA subtypes at least by ten-fold. Blocks LPA-induced contraction in urethra and prostate, as well as proliferation of prostatic stromal cells. These findings indicate a potential use of ASP 6432 for the treatment of lower urinary tract symptoms and benign prostatic hyperplasia (LUTS/BPH).